Cellceutix Corporation (OTCBB: CTIX) (“the Company”), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, is pleased to announce that it was featured Friday, January 20th on the front page of the Boston Business Journal print edition. Owned by American City Business Journals, the Boston Business Journal is available in both print and online versions and reaches hundreds of thousands of subscribers each month. Read More

Cellceutix Corporation (OTCBB:CTIX) has regularly reported significant breakthroughs in cancer research through studies of Kevetrin, the company’s novel cancer drug in development. Amazing data has been collected by Cellceutix researchers testing Kevetrin against many cancer lines, including head & neck, prostate, lung, colon, pancreatic and leukemia. Defining the Method of Action (MOA), first the p53 connection was discovered (potentially the “Holy Grail” for anticancer drugs), then the impact Kevetrin seems to have on the retinoblastoma protein. Read More

Cellceutix Corporation (OTCBB: CTIX) (“the Company”), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, is pleased to provide corporate updates on Kevetrin™, its novel drug in development for drug-resistant cancers, and KM-133, its compound being developed as a revolutionary psoriasis indication. Read More

With Contracts and IND Application in Hand, Cellceutix Nears Clinical Trials for New Cancer Drug

Cellceutix Corporation (OTCQB: CTIX), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, would like to update shareholders on recent developments regarding the impending clinical trials for Kevetrin(TM), the Company’s novel anti-cancer compound. The contracts for the clinical trials to be hosted by a world- renown cancer center have been received and reviewed, and are slated to be back at the clinical site by the end of the week. The 3,000-page Investigational New Drug (IND) Read More

The CEO of Cellceutix Corporation (OTCQB: CTIX), a preclinical cancer, anti-inflammatory and autism drug developer says his company’s leading drug candidate, Kevetrin, is a new class of chemistry in medicine which has proven to this point to restore p53 (also known as the “Guardian Angel” gene ) back to a normal status so it can do its job as master regulator and see to it that the cancer cells are destroyed without damaging any DNA. Read More

Cellceutix Corporation (OTCQB:CTIX) issued big news this morning that they have received the “thumbs-up” from one of the world’s leading cancer research centers to host the Company’s clinical trials for Kevetrin™.  Cellceutix is developing (and posting strong pre-clinical results) Kevetrin™ as an indication for a multitude of cancers including drug-resistant, pancreatic, lung, leukemia and breast cancers.  The cancer center was not disclosed, but there are several industry-leading centers in the east/northeast United States.  U.S. News recently released their list of the top cancer hospitals in the U.S.  The Top 5 included Memorial Sloan-Kettering in New York, NY; Johns Hopkins in Baltimore, MD; and Dana-Farber/Brigham and Women’s in Boston, which will have investors wondering which center will be hosting the trials Read More

Cellceutix Corporation (OTCQB:CTIX) provided shareholders with an update on the status of the Investigational New Drug filing for Kevetrin™, their lead compound as an indication for a variety of cancers. The Company has met with world-class cancer centers regarding hosting the clinical trials for Kevetrin™, a completely novel cancer therapy with strong pre-clinical data as a treatment for several strains of cancer including pancreatic, lung, breast and colon, and is now awaiting replies from the institutions. Read the full press release and get CTIX stock quote.

Facebook page now open. Take a moment to Like us.

Cellceutix Corporation (OTCQB: CTIX) reported that its anti-cancer compound, Kevetrin™, has demonstrated potent anti-tumor activity in the treatment of a pancreatic carcinoma cell line in a xenograft tumor model. After three weeks of studies, results Read More

BEVERLY, MA–(Marketwire – Jun 6, 2011) – Cellceutix Corporation (OTCQB: CTIX) (PINKSHEETS: CTIX), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, is pleased to report that its toxicology vendor, Toxikon Corporation, is currently presenting its poster “Bioanalytical Method for Kevetrin™” at the American Society for Mass Spectrometry (ASMS) meeting in Denver, CO June 5th – 9th. The poster was accepted for presentation by the ASMS and showcases Kevetrin™, the Company’s novel anti-cancer compound.

The poster explains that Kevetrin™ is a unique compound with distinctive chemistry with hydrophilicity and small molecular size. A novel HPLC-MS/MS method was successfully developed and validated for the determination of Kevetrin™ in plasma. This method met the high standards for performance requirements needed to support pre-clinical toxicology studies and IND submission to the FDA.

In Other News:

Cellceutix is pleased to report that Bilcare Global Clinical Supplies, a business unit of industry-leader Bilcare Ltd., has been contracted as a vendor for the planned clinical trials. More information on Bilcare can be found at http://www.bilcare.com/.

Cellceutix Chief Scientific Officer Dr. Krishna Menon is now attending the annual meeting of the American Society of Clinical Oncology (ASCO) for meetings with other pharmaceutical corporations and vendors.

As also announced in a press release on May 23, 2011, Cellceutix is testing Kevetrin™ against an aggressive form of pancreatic cancer before filing of the Investigational New Drug application with the FDA. The Company is pleased to report that testing is near completion.

Leo Ehrlich, CEO of Cellceutix, commented,

“It is a very busy time at Cellceutix. We are extremely pleased that Toxikon chose to present Kevetrin™ at the ASMS meeting as to what they accomplished, creating the new HPLC-MS/MS method which was another industry first. It is often difficult to help people understand the challenges behind developing Kevetrin™ as there is nothing else like it; so even what may be standard for other drugs requires a completely new process to be established for us. It is this uniqueness that we believe distinguishes Cellceutix as having one of the most promising anti-cancer compounds.”

BEVERLY, MA–(Marketwire – May 23, 2011) – Cellceutix Corporation (OTCQB: CTIX), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, announced today that in light of recent exceptional preclinical results regarding Kevetrin™, the Company believes it would be Read More